| 0.84 0.098 (13.19%) | 07-17 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.12  |
1-year : | 1.29 |
| Resists | First : | 0.96 |
Second : | 1.11 |
| Pivot price | 0.92 |
|||
| Supports | First : | 0.73 | Second : | 0.6 |
| MAs | MA(5) : | 0.81 |
MA(20) : | 0.93 |
| MA(100) : | 1.2 |
MA(250) : | 1.33 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 15 |
D(3) : | 6.8 |
| RSI | RSI(14): 43.2 |
|||
| 52-week | High : | 3.15 | Low : | 0.73 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ESLA ] has closed above bottom band by 38.2%. Bollinger Bands are 21.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.89 - 0.9 | 0.9 - 0.91 |
| Low: | 0.79 - 0.79 | 0.79 - 0.8 |
| Close: | 0.87 - 0.88 | 0.88 - 0.89 |
Estrella Immunopharma, Inc. is an early-stage biopharmaceutical enterprise focused on creating T-cell therapies for various blood cancers and solid tumors, with its primary activities centered in the United States. The company's lead investigational drugs include EB103, which is in preclinical development for diffuse large B-cell lymphoma, and EB104, intended for the treatment of both diffuse large B-cell lymphoma and acute lymphocytic leukemia. Estrella also maintains a collaborative agreement with Imugene Limited, working together to develop solid tumor therapies that integrate Imugene's CF33-CD19t product candidate with Estrella's EB103. The company is based in Emeryville, California.
Thu, 09 Jul 2026
Enterprise value to revenue forward of Estrella Immunopharma, Inc. – NASDAQ:ESLA - TradingView
Wed, 08 Jul 2026
ESLA: Abbott Cooper PLLC Announces Investigation on Behalf of Estrella Immunopharma, Inc. Stockholders - GlobeNewswire
Tue, 30 Jun 2026
Estrella Immunopharma (ESLA) investors back 2026 auditor at virtual annual meeting - Stock Titan
Sat, 27 Jun 2026
Estrella Immunopharma Inc. (ESLA) Q1 2026 Earnings: Wider-than-Expected Loss Drives Stock Volatility - dars.gov.et
Sun, 21 Jun 2026
Estrella Immunopharma Inc (ESLA) Institutional Confidence - TradingKey
Wed, 29 Apr 2026
Estrella Immunopharma CFO Xu Jiandong buys $2,594 in stock - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 43 (M) |
| Shares Float | 14 (M) |
| Held by Insiders | 60.6 (%) |
| Held by Institutions | 12.1 (%) |
| Shares Short | 89 (K) |
| Shares Short P.Month | 83 (K) |
| EPS | -0.34 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.12 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -271.5 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -8 (M) |
| Levered Free Cash Flow | -3 (M) |
| PE Ratio | -2.67 |
| PEG Ratio | 0 |
| Price to Book value | -7.33 |
| Price to Sales | 0 |
| Price to Cash Flow | -4.72 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|